NRx Pharmaceuticals, Inc.

Equities

NRXP

US6294441000

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 11:55:26 2024-03-28 am EDT 5-day change 1st Jan Change
0.509 USD -3.96% Intraday chart for NRx Pharmaceuticals, Inc. +1.84% +11.83%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Transcript : NRx Pharmaceuticals, Inc. - Shareholder/Analyst Call
NRx Pharmaceuticals, Inc., Conversio Health, LLC and Nephron Pharmaceuticals Corporation Complete Memorandum of Understanding and Collaborations with Distribution Partners for HTX-100 (IV Ketamine) CI
NRX Pharmaceuticals Announces Last Patient, Last Visit in Its Phase 2B/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression CI
NRx Pharmaceuticals, Inc. Announces Completion of Enrollment of Its Phase 2b/3 Trial of NRx-101 in Suicidal Treatment Resistant Bipolar Depression CI
NRx Pharmaceuticals Gets Fast-Track Designation for NRX-101 UTI Treatment DJ
NRx Pharmaceuticals, Inc. Announces FDA Qualified Infectious Disease Product and Fast Track Designation of NRX-101 in Complicated Urinary Tract Infection and Pyelonephritis CI
NRx Pharmaceuticals Says It Reached Nasdaq Listing Compliance MT
Transcript : NRx Pharmaceuticals, Inc. - Shareholder/Analyst Call
Nrx Pharmaceuticals Announces Election of Janet Rehnquist to Its Board of Directors CI
Transcript : NRx Pharmaceuticals, Inc. - Shareholder/Analyst Call
NRx Pharmaceuticals, Inc. Announces FDA Clearance of its Investigational New Drug Application for NRX-101 in the Treatment of Complicated Urinary Tract Infections CI
Transcript : NRx Pharmaceuticals, Inc., Q3 2023 Earnings Call, Nov 14, 2023
NRx Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
NRx Pharmaceuticals and Nephron Pharmaceuticals Announce Joint Agreement to Develop Intravenous Ketamine to Treat Suicidal Depression CI
NRx Pharmaceuticals Announces Signing of a Development Agreement for the Manufacture of Ketamine to Treat Suicidality and Depression CI
NRx Pharmaceuticals Announces Further Alignment with FDA on Initiation of Registrational Trials for NRX-101 in the Treatment of Chronic Pain CI
NRx Pharmaceuticals Announces Strategic Acceleration of its Plans to Develop Commercial Form of NRX-100 (intravenous ketamine) to Treat Acute Depression and Suicidality CI
NRx Pharmaceuticals Announces FDA Permission to Proceed on Investigational New Drug Application for NRX-101 to Treat Chronic Pain CI
NRX Pharmaceuticals Signs Data Sharing Agreement to Support FDA Submission on Suicidal Bipolar Depression Therapy MT
NRx Pharmaceuticals, Inc. Announces Data Sharing Agreement Demonstrating Efficacy and Safety of Intravenous Ketamine for Treatment of Suicidal Bipolar Depression CI
NRX Pharmaceuticals, Inc. Appoints Richard Narido, as Principal Financial Officer and Principal Accounting Officer CI
NRx Pharmaceuticals, Inc. Announces Executive Changes, Effective as of September 30, 2023 CI
NRx Pharmaceuticals, Inc. Announces New Data That Demonstrates Potent in Vitro Activity of NRx-101 CI
NRx Pharmaceuticals Announces Submission of an Investigational New Drug Application for NRX -101 in the Treatment of Chronic Pain CI
NRx Pharmaceuticals Agrees to Sell 3 Million Preferred Shares for About $1.2 Million MT
Chart NRx Pharmaceuticals, Inc.
More charts
NRX Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the development of therapeutics for the treatment of central nervous system disorders, specifically suicidal depression and post-traumatic stress disorder (PTSD). The Company's program NRX-101, an oral, fixed-dose combination of D-cycloserine and lurasidone, targets the brains N-methyl-D-aspartate (NMDA) receptor and is being investigated in a Phase III trial under the United States Food and Drug Administrations (FDA) Special Protocol Agreement and Therapy Designation in patients with bipolar depression and suicidal ideation. The Company has also initiated a Phase IIb clinical trial in patients with Sub-Acute Suicidality, a substantially broader indication. Its product, NRX-100, is racemic ketamine, which is a generic anesthetic. It is engaged in the development of aviptadil acetate (ZYESAMI) for the treatment of respiratory failure in COVID-19.
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.53 USD
Average target price
3.75 USD
Spread / Average Target
+607.55%
Consensus

Quarterly revenue - Rate of surprise

  1. Stock
  2. Equities
  3. Stock NRx Pharmaceuticals, Inc. - Nasdaq
  4. News NRx Pharmaceuticals, Inc.
  5. NRX Pharmaceuticals : Files Shelf for Up to 2.9 Million Common Shares on Behalf of Selling Securityholders